We help surgeons maximise the
healing potential of the human body
Since 2010 we have applied our deep understanding of regenerative medicine to create products that help surgeons improve the quality of life of their patients.
Our regenerative medicine solutions span treatments for bones, nerves and tendons. By advancing the science of tissue repair and regeneration, we strive to help patients recover what injury or disease has taken from them by improving mobility, function and performance.
Our product range supports surgeons to provide the best care for their patients:
Remplir™ Nerve Wrap
Remplir is a collagen nerve wrap designed for the repair of peripheral nerve injuries It provides compression-free protection to the nerve, generating an ideal microenvironment to aid nerve healing.
Learn more
OrthoACI™ Cartilage Cell Therapy
OrthoACI or Autologous Chondrocyte Implantation is a personalised cellular therapy used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI has not been authorized by MDD and is not available for sale, distribution or routine clinical use in Canada.
Learn more
Striate+™ Dental Membrane
Striate+ is collagen barrier membrane used for guided bone and tissue regeneration procedures in dental applications. It is designed to support healing by forming a protective layer over the treatment site, facilitating the regeneration of bone and tissue.
Learn more
OrthoATI™ Tendon Cell Therapy
OrthoATI or Autologous Tenocyte Implantation is a personalised cellular therapy used for the treatment tendons damaged by tendinopathy. OrthoATI has not been authorized by MDD and is not available for sale, distribution or routine clinical use in Canada.
Learn moreOur regenerative medicine solutions span treatments for bones, nerves and tendons, treating more than 75,000 patients worldwide so far.
75,000+
patients treated
worldwide
Commercialised
across multiple global
markets
US FDA
cleared for collagen-
based medical device
Backed by
clinical data and
ongoing clinical
research
Manufacturing certified
by ISO 13485 for the
manufacture of
medical devices
Licensed by the TGA for
the manufacture of
therapeutic goods
(human tissue/cell
therapies).
Real outcomes for real patients
Mobility is foundational to human connection and quality of life. For people who have experienced serious peripheral nerve damage, every recovery milestone matters – as they strive to return to normal function.
Remplir™
Measure of Hope
Meet Jasmine McGough
Nerve transfer surgery with Remplir has allowed Jas to reclaim sensation and movement in her hands and arms – giving her back independence and hope.
Discover more patient stories
Remplir™
Reclaim Independence
Meet Liam Shepherd
Since his surgery, Liam has reclaimed abilities he once thought impossible – including driving a modified car.
Discover more patient stories
Remplir™
Returning Function
Meet Damien Hall
Damien injured his hand skateboarding, seriously damaging a motor nerve and leaving him with a permanently closed fist.
Discover more patient storiesOrthocell is a leading example of the capacity for Australian biotechnology companies to translate world-class research into commercially viable and life-changing products – manufactured on home soil.
Paul Anderson
Co-Founder and Managing Director
Want to discover more about us?
Solutions
Find out how we partner with key opinion-leading health care professionals to offer new therapies for complex injuries.
Team
Learn about our expert team that develops, manufactures and commercializes regenerative medicine therapies.
Investors
Orthocell is an ASX-listed company, with a solid performance history and high growth potential. Read the latest announcements here
Latest news
Replay | Q4 FY26 Results Webinar
Orthocell has released the replay of its July investor webinar, in which Chair John Van Der Wielen, CEO and Managing Director Paul Anderson, CFO Jim Piper and VP U.S. Sales John Walker set out the strategy behind the Company’s record FY2026 results and the momentum building in its U.S. commercialisation of Remplir™. Insights from the webinar include: A foundation-first…
Orthocell delivers record quarterly and full-year revenue as global commercial momentum accelerates
Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 30 June 2026, reporting record quarterly and full-year revenue, continued growth in the United States and further expansion across international markets. Key highlights from this quarter include: Orthocell delivered record quarterly revenue of $3.8 million, representing a 20% increase on the March quarter and a 36% increase…
Orthocell Appoints Exclusive Remplir™ Distributor for Thailand
Orthocell Limited (ASX: OCC) has appointed medical device distributor MediTime as its exclusive distributor for Remplir™ in Thailand, following regulatory approval from the Thai Food and Drug Administration to commence sales into an estimated US$84 million nerve repair market. MediTime is a specialist orthopaedics and sports medicine distributor with established coverage across Thailand’s leading hospitals, medical schools and regional centres, and a…
